Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability and Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

Trial Profile

Phase 2B, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability and Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2013

At a glance

  • Drugs MSDC 0160 (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jun 2012 MR says patient number is 266, but have left as the CT.gov number for now. It definitely appears to be the same trial.
    • 09 Jun 2012 Results were presented at the 72nd Scientific Sessions of the American Diabetes Association (ADA), and in a Metabolic Solutions Development Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top